WASHINGTON (AP) — A biotech drug from Roche has become the first medicine approved to treat breast cancer before surgery, offering an earlier approach against one of the deadliest forms of the disease.
The Food and Drug Administration approved Perjeta for women with a form of early-stage breast cancer who face a high risk of having their cancer spread to other parts of the body.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.